EP3962494B1 - Pulsative gnrh administration for use in treating cognitive disorders - Google Patents
Pulsative gnrh administration for use in treating cognitive disordersInfo
- Publication number
- EP3962494B1 EP3962494B1 EP20722577.2A EP20722577A EP3962494B1 EP 3962494 B1 EP3962494 B1 EP 3962494B1 EP 20722577 A EP20722577 A EP 20722577A EP 3962494 B1 EP3962494 B1 EP 3962494B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gnrh
- mice
- ts65dn
- cognitive
- olfactory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305550 | 2019-04-30 | ||
| PCT/EP2020/061943 WO2020221821A1 (en) | 2019-04-30 | 2020-04-29 | Pulsative gnrh administration for treating cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3962494A1 EP3962494A1 (en) | 2022-03-09 |
| EP3962494B1 true EP3962494B1 (en) | 2026-03-04 |
Family
ID=66625872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20722577.2A Active EP3962494B1 (en) | 2019-04-30 | 2020-04-29 | Pulsative gnrh administration for use in treating cognitive disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220202895A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3962494B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7779739B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3962494T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067563T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020221821A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022136417A1 (en) | 2020-12-22 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pulsative gnrh administration for treating food intake related disorders |
| AU2023332041A1 (en) | 2022-09-02 | 2025-02-20 | Leibniz-Institut Für Immuntherapie (Lit) | THERAPEUTIC USE OF THE miR155 SNP rs377265631 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0158683B1 (de) | 1984-04-14 | 1988-10-05 | Ferring Biotechnik GmbH | Vorrichtung zum intermittierenden Applizieren flüssiger Arzneimittel |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US5013293A (en) | 1987-05-28 | 1991-05-07 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| WO2007041386A2 (en) | 2005-09-30 | 2007-04-12 | Vyteris, Inc. | Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch |
| WO2014110549A1 (en) * | 2013-01-14 | 2014-07-17 | The General Hospital Corporation | Methods and assays relating to rnf216 |
| WO2014179139A2 (en) * | 2013-04-30 | 2014-11-06 | Albert Einstein College Of Medicine Of Yeshiva University | TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION |
| WO2017182580A1 (en) | 2016-04-20 | 2017-10-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception |
| CN108837143B (zh) * | 2018-09-29 | 2022-03-01 | 南华大学 | 曲普瑞林的应用 |
-
2020
- 2020-04-29 JP JP2021564303A patent/JP7779739B2/ja active Active
- 2020-04-29 DK DK20722577.2T patent/DK3962494T3/da active
- 2020-04-29 US US17/607,676 patent/US20220202895A1/en active Pending
- 2020-04-29 EP EP20722577.2A patent/EP3962494B1/en active Active
- 2020-04-29 WO PCT/EP2020/061943 patent/WO2020221821A1/en not_active Ceased
- 2020-04-29 ES ES20722577T patent/ES3067563T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7779739B2 (ja) | 2025-12-03 |
| US20220202895A1 (en) | 2022-06-30 |
| DK3962494T3 (da) | 2026-04-07 |
| WO2020221821A1 (en) | 2020-11-05 |
| EP3962494A1 (en) | 2022-03-09 |
| JP2022533011A (ja) | 2022-07-21 |
| ES3067563T3 (en) | 2026-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cimino et al. | Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion | |
| Moore et al. | Kisspeptin/Neurokinin B/Dynorphin (KNDy) cells as integrators of diverse internal and external cues: evidence from viral-based monosynaptic tract-tracing in mice | |
| Messina et al. | A microRNA switch regulates the rise in hypothalamic GnRH production before puberty | |
| Hamson et al. | Sex hormones and cognition: neuroendocrine influences on memory and learning | |
| Goncalves et al. | Retinoic acid synthesis by NG2 expressing cells promotes a permissive environment for axonal outgrowth | |
| D’intino et al. | Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non‐human primate model of multiple sclerosis by correcting tissue hypothyroidism | |
| Vanacker et al. | Neuropilin‐1 expression in GnRH neurons regulates prepubertal weight gain and sexual attraction | |
| Murphy et al. | Synaptic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis | |
| Ngomba et al. | The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike–wave discharges in the WAG/Rij rat model of absence epilepsy | |
| Fu et al. | Ectopic vesicular glutamate release at the optic nerve head and axon loss in mouse experimental glaucoma | |
| Hoy et al. | Neuroligin1 drives synaptic and behavioral maturation through intracellular interactions | |
| US20220202895A1 (en) | Pulsative gnrh administration for treating cognitive disorders | |
| EP3701499A1 (en) | Treatment for skeletal diseases caused by intracellular protein trafficking defects | |
| Mohammad et al. | Functional compensation between cholecystokinin-1 and-2 receptors in murine paraventricular nucleus neurons | |
| Foutch et al. | Adolescent seizure impacts oligodendrocyte maturation, neuronal-glial circuit Formation, and myelination in the mammalian forebrain | |
| WO2017182580A1 (en) | Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception | |
| WO2016201086A1 (en) | Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein | |
| JPWO2018159787A1 (ja) | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 | |
| US10220070B2 (en) | Alphaa-crystallin mimetic peptides and uses thereof | |
| Ternier | New insights on the human and murine GnRH system through functionnal assays and 3D-imaging | |
| Lei et al. | Dual inhibition of IRAK1/TAK1 signaling in astrocytes reduces accelerated mortality in human APOE4 knock-in APPswe/PSEN1dE9/P301S-Tau triple transgenic mouse model | |
| De Guzman | Alterations in Corticotropin-Releasing Factor Receptor Type 1 in the Hypothalamus and Preoptic Area During the Postpartum Period | |
| Boxer | Cell-Type and Sex-Specific Dissection of the Ventral Subiculum Inhibitory Microcircuit and Nucleus Accumbens Projection Circuit | |
| Buren | Global neuroprotection of huntingtin in culture and alterations of cortico-striatal connections in Huntington’s disease culture and mouse models | |
| Liu | Evaluating The Contributions of Focal Subclinical Ischemia to Alzheimer’s Disease Pathogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211117 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240104 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20250926 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: F10 Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260304 Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020067941 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20260331 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260501 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3067563 Country of ref document: ES Kind code of ref document: T3 Effective date: 20260522 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: R17 Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260604 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20260506 Year of fee payment: 7 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20260304 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20260421 Year of fee payment: 7 Ref country code: DK Payment date: 20260421 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260605 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20260618 Year of fee payment: 7 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20260421 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260604 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20260501 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20260421 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20260304 |